Porton Advanced’s End-to-End CDMO Service Drives Qihan Biotech’s First-in-Class Dual-targeting CAR-T IND Approval in China
Porton Advanced and RongCan Biotech Announce Strategic Collaboration to Advance LNP Delivery Technology for Nucleic Acid and Cell Therapies
Porton Advanced and NovaCell Therapeutics Announced Strategic Cooperation to Accelerate NK Cell Therapy Development
Porton Advanced’s End-to-End Bacterial Vector CDMO Solution Accelerates FDA Approval of Salvectors’ Innovative Oncolytic Bacteria Therapy
Porton Advanced’s Comprehensive CDMO Solutions Facilitates Qihan Biotech with FDA Clearance of IND application of its First-in-Class Universal Dual-Targeting CAR-T Cell Therapy
Porton Advanced and CellStore Partner to Optimize Cryopreservation Media for More Affordable Cell Therapies
